SecBot SecBot
EFFECT ·Filed Jul 22, 2026

LYEL

Lyell Immunopharma, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC9999999995-26-002375
IPO/offering going effective
Actionable Insight • Neutral

The effective shelf creates a standing overhang of ~1.95M shares that selling stockholders can unload at any time. Monitor for a takedown notice (424B5) or insider selling volume spikes. The low dollar amount relative to market cap suggests limited immediate pressure, but the stock's low liquidity could amplify any selling. No catalyst or pipeline update is bundled with this filing.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.84
T+0 close · Jul 22, 2026 · via day close
Latest settled
−36.22%
T+60 · $8.19
Vs SPY
−39.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $12.84entry
  2. T+1 · 4mo ago −0.47%α +0.77% · $12.78
  3. T+5 · 4mo ago +1.01%α +3.41% · $12.97
  4. T+20 · 3mo ago +22.74%α +19.84% · $15.76
  5. T+60 · 5w ago −36.22%α −39.48% · $8.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma's S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026. This allows selling stockholders to resell up to 1,952,360 shares of common stock acquired in a March 2026 private placement. The company receives no proceeds from these sales, but the effectiveness introduces a potential overhang of ~1.95M shares that can be sold into the market at any time, representing approximately 0.6% of the current market cap of $321M, a modest but real dilution risk for a pre-revenue biotech with limited liquidity.

Key Facts

  • S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026.
  • Registration covers resale of 1,952,360 shares of common stock by selling stockholders.
  • Selling stockholders include institutional investors ARCH Venture Fund, Gates Frontier, and Explore Investments.
  • Lyell Immunopharma will not receive any proceeds from these share sales.
  • Shares were originally purchased at $25.61 per share in a March 6, 2026 private placement.
  • Current market cap is $321M; the registered shares represent ~0.6% of outstanding shares.

Financial Impact

Potential overhang of ~1.95M shares (~0.6% of market cap at $321M) that can be sold at any time; no proceeds to the company.

dilutionshare count

Risk Factors

  • Selling stockholders may begin selling shares immediately, creating downward price pressure.
  • Low trading liquidity could amplify the impact of any share sales.
  • No company proceeds from sales, the overhang provides no operational benefit to offset dilution.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002375
Document: 9999999995-26-002375-index.html9999999995-26-002375
Document: 9999999995-26-002375.txt9999999995-26-002375

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Viewing Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026